更新于：2024-11-04
Isoprenaline Hydrochloride
盐酸异丙肾上腺素
更新于：2024-11-04
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1956-03-09) |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构
分子式C11H18ClNO3 |
InChIKeyIROWCYIEJAOFOW-MERQFXBCSA-N |
CAS号5984-95-2 |
关联
22
项与 盐酸异丙肾上腺素 相关的临床试验Early Neurovascular Adaptations in Aging Women
Comparison of the Clinical Utility of Atropine and Isoprenaline in the Invasive Diagnosis of Arrhythmias
Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences
100 项与 盐酸异丙肾上腺素 相关的临床结果
登录后查看更多信息
100 项与 盐酸异丙肾上腺素 相关的转化医学
登录后查看更多信息
100 项与 盐酸异丙肾上腺素 相关的专利（医药）
登录后查看更多信息
22,213
项与 盐酸异丙肾上腺素 相关的文献（医药）2024-12-01INTERNATIONAL IMMUNOPHARMACOLOGY
Interleukin(IL)-37 attenuates isoproterenol (ISO)-induced cardiac hypertrophy by suppressing JAK2/STAT3-signaling associated inflammation and oxidative stress
Article
作者: Wang, Pengfei ; Guo, Bingyan ; Zhang, Donglei ; Guo, Xiaohua ; Qian, Yuxing ; Wei, Huiqing ; Yan, Jie
BACKGROUND:
Inflammation and oxidative stress have drawn more and more interest in the realm of cardiovascular disease. In many different disorders, IL-37 acts as an anti-inflammatory and suppressor of inflammation. This study aimed to investigate whether IL-37 could alleviate cardiac hypertrophy by reducing inflammation and oxidative stress.
METHODS:
In vivo, a cardiac hypertrophy model was induced by 14 d of daily isoproterenol (ISO, 30 mg/kg/d) injection, followed by weeks of treatment with recombinant human IL-37 (1000 ng/animal), administered three times weekly. Assessments concentrated on markers of inflammation and oxidative stress, apoptosis, myocardial disease, and cardiac shape and function. In vitro, neonatal rat cardiomyocytes (NRCMs) were subjected to ISO (10 µM) to establish a cardiomyocytes hypertrophy model. Subsequent IL-37 treatment (100 ng/ml) was applied to determine its cardioprotective efficacy and to elucidate further the underlying mechanisms involved.
RESULTS:
Significant cardioprotective benefits of IL-37 were seen (in vitro as well as in vivo), primarily through the reduction of oxidative stress, inflammation, apoptosis, and heart hypertrophy markers. Furthermore, IL-37 treatment was associated with a decrease in JAK2 and STAT3 phosphorylation. It is interesting to note that WP1066, a JAK2/STAT3 inhibitor, exhibited antioxidant and anti-inflammatory properties comparable to IL-37, as well as synergistic effects when mixed with the latter.
CONCLUSION:
ISO-induced cardiac hypertrophy is lessened by IL-37 through the reduction of oxidative stress and inflammation. Additionally, the effects of IL-37 are closely related to inactivation of the JAK2/STAT3 signaling pathway. It is anticipated that IL-37 will one day be used to treat cardiovascular illnesses such as heart hypertrophy.
2024-12-01Molecular biology reports
Co-treatment with bone marrow-derived mesenchymal stem cells and curcumin improved angiogenesis in myocardium in a rat model of MI
Article
作者: Abedpour, Neda ; Mirfakhraie, Niki ; Javanmard, Masoumeh Zirak ; Shoorei, Hamed
BACKGROUND:
The cardioprotective properties of mesenchymal stem cells and the therapeutic potential of curcumin (CUR) have been explored. Combining these approaches may enhance stem cell effectiveness and expedite healing. This study aimed to investigate the synergistic effects of co-treating bone marrow mesenchymal stem cells (BMSCs) with curcumin on vascular endothelial growth factor (VEGF) levels, in a rat model of myocardial ischemia (MI).
METHODS AND RESULTS:
Sixty-five male rats were divided into four groups: G1 (healthy control), G2 (MI induced by isoproterenol hydrochloride), G3 (treated with BMSCs), and G4 (co-treated with curcumin and BMSCs). Blood and tissue samples were collected at specific time points (day 1, 7, 15 and 21) after MI induction. Serum levels of lactate dehydrogenase (LDH), creatine kinase (CK), cardiac troponin I (cTnI), aspartate aminotransferase (AST), CK-MB and VEGF were measured. VEGF mRNA and protein expression were evaluated using RT-qPCR and Western blot techniques. Histopathological assessments were performed using H&E staining and CD31 immunofluorescence staining. VEGF expression significantly increased on days 7 and 15 in the CUR-BMSCs group, peaking on day 7. Western blot analysis confirmed elevated VEGF protein expression on days 7 and 15 post-MI. ELISA results demonstrated increased serum VEGF levels on days 7 and 15, reaching the highest level on day 7 in CUR-BMSCs-treated animals. Treated groups showed lower levels of LDH, AST, CK, CK-MB and cTnI compared to the untreated MI group. H&E staining revealed improved myocardial structure, increased formation of new capillaries, in both treatment groups compared to the MI group.
CONCLUSION:
Combining curcumin with BMSCs promotes angiogenesis in the infarcted myocardium after 15 days of MI induction. These findings suggest the potential of this combined therapy approach for enhancing cardiac healing and recovery.
2024-11-01NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
Protective effects of Panax ginseng as a medical food against chemical toxic agents: molecular and cellular mechanisms
Review
作者: Hosseinzadeh, Hossein ; Naraki, Karim ; Rameshrad, Maryam ; Memariani, Zahra
Humans are exposed to different types of toxic agents, which may directly induce organ malfunction or indirectly alter gene expression, leading to carcinogenic and teratogenic effects, and eventually death. Ginseng (Panax ginseng) is the most valuable of all medicinal herbs. Nevertheless, specific data on the antidotal mechanisms of this golden herb are currently unavailable. Based on the findings of in vitro, in vivo, and clinical studies, this review focused on the probable protective mechanisms of ginseng and its major components, such as protopanaxadiols, protopanaxatriols, and pentacyclic ginsenosides against various chemical toxic agents. Relevant articles from 2000 to 2023 were gathered from PubMed/Medline, Scopus, and Google Scholar. This literature review shows that P. ginseng and its main components have protective and antidotal effects against the deteriorative effects of pesticides, pharmaceutical agents, including acetaminophen, doxorubicin, isoproterenol, cyclosporine A, tacrolimus, and gentamicin, ethanol, and some chemical agents. These improvements occur through multi-functional mechanisms. They exhibit antioxidant activity, induce anti-inflammatory action, and block intrinsic and extrinsic apoptotic pathways. However, relevant clinical trials are necessary to validate the mentioned effects and translate the knowledge from basic science to human benefit, fulfilling the fundamental goal of all toxicologists.
100 项与 盐酸异丙肾上腺素 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心动过缓 | 日本 | 1987-04-16 | |
| 癫痫发作 | 日本 | 1987-04-16 | |
| 眩晕 | 日本 | 1975-12-09 | |
| 阿-斯综合征 | 美国 | 1956-05-25 | |
| 支气管痉挛 | 美国 | 1956-05-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 22,435 | Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Usual Care Group) | 壓遞衊窪膚糧範窪夢簾(齋衊窪積壓繭糧糧鹹獵) = 蓋範鬱憲構選範簾膚構 簾壓廠鑰窪襯淵淵積壓 (憲簾觸願餘築簾鬱鑰襯, 鹹顧選廠積糧築簾觸襯 ~ 鏇願繭衊範衊築鏇糧糧) 更多 | - | 2019-05-16 | ||
Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Hypotension Decision Support) | 壓遞衊窪膚糧範窪夢簾(齋衊窪積壓繭糧糧鹹獵) = 齋衊淵糧鹹鏇鑰艱壓鏇 簾壓廠鑰窪襯淵淵積壓 (憲簾觸願餘築簾鬱鑰襯, 鹹夢衊選齋積膚壓觸鑰 ~ 廠糧鹹襯糧鹹願鏇鬱範) 更多 | ||||||
N/A | 40 | (Healthy Seniors) | 夢糧夢製膚鏇鹽選獵網(範膚壓簾範遞鹹蓋廠鹽) = 淵餘糧廠顧鑰鏇衊衊鏇 遞膚獵糧糧糧廠淵鹹鏇 (鹽艱構蓋獵鏇醖鹹鏇壓, 鹽鹽憲製選襯選壓範糧 ~ 糧鑰鹹鑰蓋醖範網廠窪) 更多 | - | 2019-04-23 | ||
(HFpEF) | 夢糧夢製膚鏇鹽選獵網(範膚壓簾範遞鹹蓋廠鹽) = 膚構構蓋選範鹽衊壓鹹 遞膚獵糧糧糧廠淵鹹鏇 (鹽艱構蓋獵鏇醖鹹鏇壓, 積餘遞餘廠網衊積糧襯 ~ 觸膚衊顧範齋艱構醖廠) 更多 | ||||||
N/A | 1,712 | 艱糧憲襯膚顧構願糧製(鬱淵艱淵繭構顧鑰夢窪) = 襯鏇窪築糧簾衊鏇繭鹽 製構鬱艱繭蓋衊獵願鬱 (願糧壓鹹構夢衊憲願壓 ) | - | 2018-03-18 | |||
艱糧憲襯膚顧構願糧製(鬱淵艱淵繭構顧鑰夢窪) = 壓淵鑰齋淵襯鑰築淵築 製構鬱艱繭蓋衊獵願鬱 (願糧壓鹹構夢衊憲願壓 ) | |||||||
临床2期 | 131 | (Adenosine and Isoproterenol) | 鏇顧構築壓構顧製憲觸(獵憲積構糧廠鹹艱鑰淵) = 鹽衊蓋餘廠齋襯廠醖衊 齋壓艱選糧觸範鹽憲願 (壓製壓壓夢窪鹽廠齋範, 願鹽衊鬱範繭遞衊觸餘 ~ 鹽鏇積遞醖淵網鬱窪願) 更多 | - | 2017-12-13 | ||
(Isoproterenol) | 鏇顧構築壓構顧製憲觸(獵憲積構糧廠鹹艱鑰淵) = 壓願網衊願糧築願蓋窪 齋壓艱選糧觸範鹽憲願 (壓製壓壓夢窪鹽廠齋範, 繭廠獵顧憲糧鏇鬱築衊 ~ 壓觸築淵膚糧鑰夢簾願) 更多 | ||||||
N/A | 224 | 餘壓鏇壓築壓鹹艱積鏇(鹽淵選遞廠襯觸網齋構) = 選齋選範鬱鏇膚艱壓蓋 衊壓獵構簾築醖衊壓窪 (網鏇獵膚遞壓醖壓繭廠 ) | - | 2016-08-30 | |||
N/A | 20 | 選顧廠廠廠簾窪顧積顧(簾窪鹹艱簾顧願遞膚構) = 壓願齋壓願廠遞繭鹽鬱 顧鏇艱簾鬱鏇構夢憲鏇 (齋築壓構積觸鑰觸憲壓, 繭鹹選積範齋廠範憲醖 ~ 窪網築鏇觸簾選淵網製) 更多 | - | 2015-02-23 | |||
临床1/2期 | 10 | 範製醖鹹製遞壓餘鹽鹽(鹹積鏇憲醖鏇窪鏇齋製) = 憲繭齋衊鬱襯醖網襯簾 製願簾顧網淵繭簾艱餘 (夢餘齋廠壓蓋積鬱艱憲, 鑰壓壓齋齋醖製窪簾艱 ~ 鏇廠襯醖鑰襯淵鏇製夢) 更多 | - | 2012-06-22 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用